Prediction of cardiovascular adverse events in newly diagnosed multiple myeloma: Development and validation of a risk score prognostic model

BACKGROUND: Multiple myeloma (MM) is the second most common hematological malignancy, and the treatments markedly elevate the survival rate of the patients in recent years. However, the prevalence of cardiovascular adverse events (CVAEs) in MM had been increasing recently. CVAEs in MM patients are a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Shuai, Zhou, Jie-Yi, Yang, Ben-Zhao, Xie, Zhong-Lei, Zhu, Ting-Jun, Hu, Hui-Xian, Li, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070977/
https://www.ncbi.nlm.nih.gov/pubmed/37025590
http://dx.doi.org/10.3389/fonc.2023.1043869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070977/
https://www.ncbi.nlm.nih.gov/pubmed/37025590
http://dx.doi.org/10.3389/fonc.2023.1043869

Ejemplares similares